You're seeing this message because you're using an older version of Internet Explorer that is unsupported on our website. Please use these links to upgrade to a modern web browser that fully supports our website and protects your computer from security risks.

Mozilla Firefox

Mozilla Firefox

Google Chrome

Google Chrome

Internet Explorer 8

Hide this message

FSU Tag Line

Meningitis Information

Meningococcal: Questions and Answers

On this Page:


The Disease

What causes meningococcal disease?

Meningococcal disease is caused by the bacterium Neisseria meningitides, also known as meningococcus.

What are the symptoms?

The most common symptoms are high fever, chills, lethargy, and a rash. If meningitis is present, the symptoms will also include headache and neck stiffness; seizures may also occur. In overwhelming meningococcal infections, shock, coma and death can follow within several hours, even with appropriate medical treatment.

How is the disease spread?

The infection is spread person-to-person through the exchange of respiratory and throat secretions (e.g. by coughing, kissing or sharing eating utensils). Meningococcal bacteria can't live for more than a few minutes outside the body, so the disease is not spread as easily as the common cold or influenza.

How common is meningococcal disease?

There are approximately 2,000 - 3,000 cases of meningococcal disease each year in the United States. An estimated 110 deaths from meningococcal disease occurred in the United States in 2009.

Who is at risk for meningococcal meningitis?

Anyone can get meningococcal disease. Certain groups, though are at higher risk. These include infants, adolescents and college students, particularly freshman living in dormitories. Disease rates decline after infancy, but begin to rise again in early adolescence, peaking between the ages of 15 and 19 years.

People with certain medical conditions as those who have a damaged spleen, or whose spleen has been removed, or those who have certain immune system disorders (terminal complement component deficiency). Other individuals as military recruits, and persons who travel or reside in countries in which N. meningitidis is hyper endemic are also at increased risk.

Why are college students at greater risk for meningococcal disease than the general population?

While the reasons are not yet fully understood, studies from previous college outbreaks suggest that college students are more susceptible because they live and work in close proximity to each other in dormitories and classrooms. Behavioral and social aspects of college life appear to be risk factors as well, with smoking, exposure to second-hand smoke, excessive alcohol consumption, and bar patronage all increasing the chance that one will contract meningitis from an infected individual.

The Vaccine

Is there any way for college students to protect themselves against the threat of meningococcal disease?

Two types of meningococcal vaccines are available in the US

  • Meningococcal Polysaccharide vaccine (MPSV4) also known as Menomune has been available since the 1970's
  • Meningococcal Conjugate vaccine (MCV4) also know as Menactra licensed in 2005. A second conjugate vaccine, Menveo was licensed in 2010.

Both vaccines can prevent 4 types of meningococcal disease (A, C, Y and W-135). In persons 15 - 24 years of age, 70% - 80% of cases are caused by potentially vaccine-preventable strains.

Both the vaccines work well, and protect more than 90% of those who get it. MCV4 (Menactra or Menveo) gives longer-lasting protection and should also be better at preventing the disease from spreading from person to person.

Should college students be vaccinated against meningococcal disease?

College freshmen, especially those living in dormitories, are at increased risk of meningococcal disease. The MCV4 vaccine (Menactra or Menveo) is recommended for person 19 - 21 years old if they are entering college or are in a college or university setting. Although the risk for meningococcal disease among non-freshmen college students is similar to that of the general population of the same age, there is no medical reason that other students who wish to decrease their risk of meningococcal disease cannot receive the vaccine.

Are booster doses needed following initial vaccination?

Yes, all adolescents who were first vaccinated at ages 11 - 12 years need a booster at age 16 years; all teens who were vaccinated at ages 13 - 15 years need a booster at age 16 - 18 years.
Young adults ages 19 - 21 years who are living in on-campus housing should get a booster dose if their previous dose was given before age 16 years.

What are the side effects of the vaccine? How safe is it?

The meningococcal vaccines have an excellent safety profile. Side effects are mild and consist primarily of redness and swelling at the site of injection lasting up to two days.

Meningococcal immunization should be deferred during any acute illness. The vaccine should not be administered to individuals sensitive to any of the components of the vaccine.

How effective is the vaccine?

The MPSV4 vaccine (Menomune) has been shown to create protective levels of antibodies against the four most common strains of meningococcus in over 85% of adults studied. As with any vaccine, meningococcal vaccination may not protect 100% of susceptible individuals. Protection from the vaccine lasts for about 3-5 years.

The MCV4 vaccine (Menactra/Menveo) has been shown to create equally effective levels of protection as MPSV4 and to have a longer duration of immunity.

Can college students do anything else to reduce the risk of contracting meningococcal disease?

Maximize your body's own immune response. Eat a balanced diet, and get adequate sleep and exercise. Avoid cigarettes and excessive use of alcohol. In particular, do not make a habit of sharing drinks and cigarettes.

Insurance Information

Will my insurance company reimburse for this vaccine?

Many insurance companies do cover the cost of the meningitis vaccine. To help you work with your insurance company for reimbursement, we have provided this Frequently Asked Questions sheet. The student will also receive a copy of his/her Encounter Receipt, at the time of vaccination, with the following insurance billing information:

  • Procedure Code 90733 (Menomune) or 90734 (Menactra/Menveo)
  • Diagnosis Code V03.89


You may submit this information as a claim for reimbursement. However, there is no guarantee that you will be reimbursed.


A waiver form must be signed for those students living in on campus housing choosing NOT to receive the vaccine. This is found on Residence Life Contract Form.